Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

Amgen

Overview

Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Non-Hodgkin's Lymphoma

Interventions

epratuzumabDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL \* Received and failed at least 1 prior regimen of chemotherapy \* Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.